Teva Pharmaceutical Industries Ltd. $TEVA Holdings Lessened by Bourgeon Capital Management LLC

Bourgeon Capital Management LLC reduced its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 15.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 611,345 shares of the company’s stock after selling 108,655 shares during the period. Teva Pharmaceutical Industries comprises 3.1% of Bourgeon Capital Management LLC’s portfolio, making the stock its 5th largest position. Bourgeon Capital Management LLC owned 0.05% of Teva Pharmaceutical Industries worth $19,080,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TEVA. AQR Capital Management LLC boosted its position in Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares during the last quarter. Focus Partners Wealth increased its position in shares of Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after acquiring an additional 1,739 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the second quarter worth about $255,000. Rhumbline Advisers lifted its stake in shares of Teva Pharmaceutical Industries by 2.3% in the second quarter. Rhumbline Advisers now owns 287,401 shares of the company’s stock worth $4,817,000 after acquiring an additional 6,339 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Teva Pharmaceutical Industries by 14.2% in the second quarter. American Century Companies Inc. now owns 260,808 shares of the company’s stock valued at $4,371,000 after purchasing an additional 32,388 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 6.2%

Shares of Teva Pharmaceutical Industries stock opened at $30.12 on Wednesday. The business has a 50-day moving average price of $32.24 and a 200 day moving average price of $27.61. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The firm has a market cap of $34.63 billion, a P/E ratio of 25.10, a P/E/G ratio of 9.52 and a beta of 0.72. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.Teva Pharmaceutical Industries’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 17,295 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the sale, the executive vice president owned 85,755 shares in the company, valued at $2,715,860.85. The trade was a 16.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Sabag sold 62,102 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the sale, the insider directly owned 224,940 shares in the company, valued at $6,779,691.60. This trade represents a 21.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 920,901 shares of company stock valued at $30,056,789 over the last quarter. Insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on TEVA. Scotiabank raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.